Spago Nanomedical in media

• 16 Oct, 2025
  Spagos CEO comments on Proof-of-Concept milestone – BioStock
• 9 Jun, 2025
  Spago’s phase I/IIa cancer study on track for 2025 completion – Biostock
• 6 Mar, 2025
  Spago takes Tumorad-01 study to the next level – BioStock
• 19 Dec, 2024
  Spago’s CEO: We want to expand cancer treatment with effective radiopharmaceuticals – BioStock
• 7 May, 2024
  Spagos CEO: Advancing the Tumorad programme comes first – BioStock
• 27 Mar, 2024
  Spago Nanomedicals CEO: “huge commercial opportunities are unfolding – BioStock
• 9 Feb, 2024
  Springboard forspagos radionuclide cancer therapy – BioStock
• 15 Jan, 2024
  Spago’s phase I/IIa cancer trial progressing steadily – BioStock
• 20 Dec, 2023
  Positive data in Spago’s phase IIa endometriosis trial – BioStock
• 14 Dec, 2023
  First patient dosed in Spago’s phase I/IIa trial – BioStock